MARKET INTRODUCTION
Mesalamine is used in the treatment of ulcerative colitis (a condition which causes swelling in the lining of the colon) and other inflammatory bowel diseases. It is a prescription drug and contains 5-aminosalicylic acid, which helps in reducing inflammation in the intestine.
MARKET DYNAMICS
Ulcerative colitis (UC) is a chronic disease of the GI tract that causes mucosal inflammation in the colon. The increasing prevalence of ulcerative colitis and inflammatory disorders is increasing the demand of mesalamine. Inflammatory bowel disease such as Crohn's disease and Crohn's disease affects a vast population worldwide. For instance, as per the Colitis Foundation of America, approximately 1.6 million Americans are suffering from IBD. Moreover, increasing research and development and improving healthcare expenditure in developing countries is further facilitating the growth of the market.
MARKET SCOPE
The "Global Mesalamine Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of mesalamine market with detailed market segmentation by dosage form, application, and geography. The global mesalamine market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading mesalamine market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global mesalamine market is segmented on the basis of dosage from and application. Based on dosage form, the market is segmented into capsule and tablets. Based on application, the market is segmented as ulcerative colitis, Crohn's disease and other inflammatory diseases.

?
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global mesalamine market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The mesalamine market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting mesalamine market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the mesalamine market in these regions.
MARKET PLAYERS
The report covers key developments in the mesalamine market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from mesalamine market are anticipated to lucrative growth opportunities in the future with the rising demand for mesalamine market in the global market. Below mentioned is the list of few companies engaged in the mesalamine market.
The report also includes the profiles of key mesalamine market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Mylan N.V.
- Teva Pharmaceuticals
- Ferring B.V.
- Allergan
- Bausch Health Companies Inc
- Zydus Cadila
- COSMO PHARMACEUTICALS
- Tillotts Pharma AG
- Shire plc
- Pfizer
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.